Minimal residual disease in chronic lymphocytic leukaemia

被引:0
|
作者
Garcia Vela, Jose Antonio [1 ]
Garcia Marco, Jose Antonio [2 ]
机构
[1] Hosp Univ Getafe, Serv Hematol & Hemoterapia, Lab Citometria Flujo, Madrid, Spain
[2] Hosp Univ Puerta de Hierro, Serv Hematol & Hemoterapia, Lab Genet Mol, Madrid, Spain
来源
MEDICINA CLINICA | 2018年 / 150卷 / 04期
关键词
Chronic lymphocytic leukemia; Flow cytometry; Ibrutinib; Idelalisib; Venetoclax; Obinutuzumab; Minimal residual disease; TIME QUANTITATIVE PCR; INDEPENDENT PREDICTOR; PROGRESSION-FREE; FREE SURVIVAL; PHASE-II; IBRUTINIB; RITUXIMAB; CLL; EVOLUTION; THERAPY;
D O I
10.1016/j.medcli.2017.06.067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Minimal residual disease (MRD) assessment is an important endpoint in the treatment of chronic lymphocytic leukaemia (CLL). It is highly predictive of prolonged progression-free survival (PFS) and overall survival and could be considered a surrogate for PFS in the context of chemoimmunotherapy based treatment. Evaluation of MRD level by flow cytometry or molecular techniques in the era of the new BCR and Bcl-2 targeted inhibitors could identify the most cost-effective and durable treatment sequencing. A therapeutic approach guided by the level of MRD might also determine which patients would benefit from an early stop or consolidation therapy. In this review, we discuss the different MRD methods of analysis, which source of tumour samples must be analysed, the future role of the detection of circulating tumour DNA, and the potential role of MRD negativity in clinical practice in the modern era of CLL therapy. (C) 2017 Elsevier Espatia, S.L.U. All rights reserved.
引用
收藏
页码:144 / 149
页数:6
相关论文
共 50 条
  • [1] Minimal residual disease assessment in chronic lymphocytic leukaemia
    Sayala, Hazem A.
    Rawstron, Andy C.
    Hillmen, Peter
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (03) : 499 - 512
  • [2] Minimal residual disease in chronic lymphocytic leukaemia:: is it ready for primetime?
    Nabhan, Chadi
    Coutre, Steven
    Hillmen, Peter
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (03) : 379 - 392
  • [3] Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?
    Fink, Anna M.
    LANCET HAEMATOLOGY, 2019, 6 (09): : E441 - E442
  • [4] Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia
    Kwok, Marwan
    Rawstron, Andy
    Varghese, Abraham
    Evans, Paul
    O'Connor, Sheila
    Doughty, Chi
    Newton, Darren
    Moreton, Paul
    Hillmen, Peter
    LANCET, 2014, 383 : 66 - 66
  • [5] Investigating minimal residual disease in chronic lymphocytic leukaemia using fluorescent in situ hybridisation
    Williamson, G. J.
    Clark, J.
    Manasse, B.
    Follows, G.
    Foroni, L.
    Scott, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 89 - 89
  • [6] Minimal residual disease in chronic myeloid leukaemia
    Cross, NCP
    HEMATOLOGY AND CELL THERAPY, 1998, 40 (05) : 224 - 228
  • [7] Detection of minimal residual disease in B-cell chronic lymphocytic leukaemia by flow cytometry
    Vela, JAG
    Delgado, I
    Alonso, LG
    Monteserin, MC
    Benito, L
    Ona, F
    Lastra, AM
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (02) : 464 - 465
  • [8] ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia
    De Propris, Maria Stefania
    Intoppa, Stefania
    Milani, Maria Laura
    Mariglia, Paola
    Nardacci, Maria Grazia
    Peragine, Nadia
    Foa, Robin
    Guarini, Anna
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (06) : e346 - e349
  • [10] Ovarian minimal residual disease in chronic myeloid leukaemia
    Abir, Ronit
    Aviram, Adina
    Feinmesser, Meora
    Stein, Jerry
    Yaniv, Isaac
    Parnes, Doris
    Ben-Haroush, Avi
    Meirow, Dror
    Rabizadeh, Esther
    Fisch, Benjamin
    REPRODUCTIVE BIOMEDICINE ONLINE, 2014, 28 (02) : 255 - 260